Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wise said to be exploring UK banking license

(Sharecast News) - International payments firm Wise was said to be exploring the possibility of becoming a UK-licensed bank, according to the Times, with the firm said to be in early-stage discussions with regulators about the feasibility of securing a banking licence. If successful, the move will allow Wise to offer interest-bearing accounts and potentially issue loans-services currently off-limits under its existing electronic money licence. It would also bring the firm under the remit of the Financial Services Compensation Scheme, offering deposit protection up to £85,000 per customer and aligning Wise with traditional banks in terms of consumer safeguards.

Wise has not yet committed to making a formal application, with any move requiring significant investment in compliance, risk management, and regulatory infrastructure. The potential shift comes amid growing competition in the fintech space, with rivals such as Revolut and Monzo already offering full banking services.

As of 0900 BST, Wise shares were up 1.33% at 1,068p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.